vs

Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

AlTi Global, Inc. is the larger business by last-quarter revenue ($86.6M vs $74.7M, roughly 1.2× Health Catalyst, Inc.). AlTi Global, Inc. runs the higher net margin — -15.1% vs -121.9%, a 106.8% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-52.2M). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs -0.0%).

Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ALTI vs HCAT — Head-to-Head

Bigger by revenue
ALTI
ALTI
1.2× larger
ALTI
$86.6M
$74.7M
HCAT
Growing faster (revenue YoY)
ALTI
ALTI
+93.2% gap
ALTI
87.0%
-6.2%
HCAT
Higher net margin
ALTI
ALTI
106.8% more per $
ALTI
-15.1%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$61.9M more FCF
HCAT
$9.6M
$-52.2M
ALTI
Faster 2-yr revenue CAGR
ALTI
ALTI
Annualised
ALTI
30.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALTI
ALTI
HCAT
HCAT
Revenue
$86.6M
$74.7M
Net Profit
$-13.1M
$-91.0M
Gross Margin
Operating Margin
-2.1%
-115.3%
Net Margin
-15.1%
-121.9%
Revenue YoY
87.0%
-6.2%
Net Profit YoY
75.6%
-340.3%
EPS (diluted)
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALTI
ALTI
HCAT
HCAT
Q4 25
$86.6M
$74.7M
Q3 25
$57.2M
$76.3M
Q2 25
$53.1M
$80.7M
Q1 25
$58.0M
$79.4M
Q4 24
$46.3M
$79.6M
Q3 24
$51.8M
$76.4M
Q2 24
$49.5M
$75.9M
Q1 24
$50.8M
$74.7M
Net Profit
ALTI
ALTI
HCAT
HCAT
Q4 25
$-13.1M
$-91.0M
Q3 25
$-84.1M
$-22.2M
Q2 25
$-24.4M
$-41.0M
Q1 25
$1.9M
$-23.7M
Q4 24
$-53.8M
$-20.7M
Q3 24
$-72.5M
$-14.7M
Q2 24
$-6.4M
$-13.5M
Q1 24
$29.7M
$-20.6M
Gross Margin
ALTI
ALTI
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
ALTI
ALTI
HCAT
HCAT
Q4 25
-2.1%
-115.3%
Q3 25
-49.8%
-22.9%
Q2 25
-56.7%
-46.0%
Q1 25
-23.3%
-25.4%
Q4 24
-42.7%
-22.0%
Q3 24
-18.4%
-17.9%
Q2 24
-30.2%
-20.8%
Q1 24
-28.9%
-30.5%
Net Margin
ALTI
ALTI
HCAT
HCAT
Q4 25
-15.1%
-121.9%
Q3 25
-147.0%
-29.1%
Q2 25
-45.9%
-50.8%
Q1 25
3.3%
-29.9%
Q4 24
-116.1%
-26.0%
Q3 24
-140.0%
-19.3%
Q2 24
-12.9%
-17.8%
Q1 24
58.4%
-27.6%
EPS (diluted)
ALTI
ALTI
HCAT
HCAT
Q4 25
$-1.29
Q3 25
$-0.32
Q2 25
$-0.33
$-0.59
Q1 25
$-0.04
$-0.35
Q4 24
$-0.71
$-0.33
Q3 24
$-0.88
$-0.24
Q2 24
$-0.18
$-0.23
Q1 24
$0.18
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALTI
ALTI
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$41.2M
$95.7M
Total DebtLower is stronger
$883.0K
$153.3M
Stockholders' EquityBook value
$600.1M
$245.8M
Total Assets
$1.2B
$502.6M
Debt / EquityLower = less leverage
0.00×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALTI
ALTI
HCAT
HCAT
Q4 25
$41.2M
$95.7M
Q3 25
$35.8M
$91.5M
Q2 25
$42.4M
$97.3M
Q1 25
$52.8M
$342.0M
Q4 24
$64.4M
$392.0M
Q3 24
$220.6M
$387.3M
Q2 24
$60.0M
$308.3M
Q1 24
$134.2M
$327.8M
Total Debt
ALTI
ALTI
HCAT
HCAT
Q4 25
$883.0K
$153.3M
Q3 25
$586.0K
$153.1M
Q2 25
$673.0K
$153.0M
Q1 25
$382.9M
Q4 24
$0
$382.4M
Q3 24
$128.4M
$345.0M
Q2 24
$164.0M
Q1 24
$183.7M
Stockholders' Equity
ALTI
ALTI
HCAT
HCAT
Q4 25
$600.1M
$245.8M
Q3 25
$607.2M
$331.9M
Q2 25
$685.4M
$347.5M
Q1 25
$665.2M
$376.8M
Q4 24
$658.4M
$365.2M
Q3 24
$707.0M
$355.0M
Q2 24
$540.2M
$357.0M
Q1 24
$510.9M
$357.2M
Total Assets
ALTI
ALTI
HCAT
HCAT
Q4 25
$1.2B
$502.6M
Q3 25
$1.2B
$587.1M
Q2 25
$1.2B
$616.2M
Q1 25
$1.2B
$891.5M
Q4 24
$1.3B
$858.9M
Q3 24
$1.4B
$813.0M
Q2 24
$1.3B
$691.7M
Q1 24
$1.3B
$695.1M
Debt / Equity
ALTI
ALTI
HCAT
HCAT
Q4 25
0.00×
0.62×
Q3 25
0.00×
0.46×
Q2 25
0.00×
0.44×
Q1 25
1.02×
Q4 24
0.00×
1.05×
Q3 24
0.18×
0.97×
Q2 24
0.30×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALTI
ALTI
HCAT
HCAT
Operating Cash FlowLast quarter
$-51.4M
$9.9M
Free Cash FlowOCF − Capex
$-52.2M
$9.6M
FCF MarginFCF / Revenue
-60.3%
12.9%
Capex IntensityCapex / Revenue
0.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALTI
ALTI
HCAT
HCAT
Q4 25
$-51.4M
$9.9M
Q3 25
$-53.5M
$-464.0K
Q2 25
$-19.9M
$-9.0M
Q1 25
$-30.2M
$280.0K
Q4 24
$-50.7M
$-3.5M
Q3 24
$-4.9M
$6.2M
Q2 24
$-30.2M
$1.6M
Q1 24
$-15.5M
$10.3M
Free Cash Flow
ALTI
ALTI
HCAT
HCAT
Q4 25
$-52.2M
$9.6M
Q3 25
$-719.0K
Q2 25
$-20.0M
$-9.2M
Q1 25
$-31.0M
$-390.0K
Q4 24
$-58.2M
$-3.9M
Q3 24
$-9.4M
$5.5M
Q2 24
$-31.2M
$1.3M
Q1 24
$-15.7M
$10.1M
FCF Margin
ALTI
ALTI
HCAT
HCAT
Q4 25
-60.3%
12.9%
Q3 25
-0.9%
Q2 25
-37.6%
-11.4%
Q1 25
-53.4%
-0.5%
Q4 24
-125.7%
-4.9%
Q3 24
-18.2%
7.2%
Q2 24
-63.2%
1.7%
Q1 24
-30.9%
13.5%
Capex Intensity
ALTI
ALTI
HCAT
HCAT
Q4 25
0.9%
0.4%
Q3 25
0.0%
0.3%
Q2 25
0.0%
0.3%
Q1 25
1.3%
0.8%
Q4 24
16.3%
0.5%
Q3 24
8.7%
0.9%
Q2 24
2.2%
0.4%
Q1 24
0.4%
0.3%
Cash Conversion
ALTI
ALTI
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
-15.80×
Q4 24
Q3 24
Q2 24
Q1 24
-0.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALTI
ALTI

Management Advisory Fees$51.1M59%
Other$32.7M38%
Distributions From Investments$2.9M3%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons